A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies-Reference-Cited by-同舟云学术

A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies

Published:2023-08-16 Issue:4 Volume:203 Page:546-563
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Scully M.¹^ORCID,Rayment R.²,Clark A.³,Westwood J. P.⁴,Cranfield T.⁵,Gooding R.⁶,Bagot C. N.⁷,Taylor A.⁸,Sankar V.⁹,Gale D.¹⁰,Dutt T.¹¹,McIntyre J.¹²,Lester W.¹³^ORCID,

Affiliation:

1. Department of Haematology, UCLH and Haematology Programme University College London Hospitals Biomedical Research Centre, National Institute for Health Research London UK

2. Department of Haematology University Hospital of Wales Cardiff UK

3. Department of Haematology University Hospitals Bristol NHS Foundation Trust Bristol UK

4. Department of Haematology UCLH London UK

5. Department of Haematology Portsmouth Hospitals University NHS Trust Portsmouth UK

6. Haematology Department Belfast City Hospital, Belfast H&SC Trust Belfast UK

7. Glasgow Royal Infirmary Glasgow UK

8. Great Ormond Street Hospital for Children NHS Foundation Trust London UK

9. Department of Critical Care Medicine Liverpool University Hospitals NHS Foundation Trust Liverpool UK

10. Department of Renal Medicine University College London London UK

11. Liverpool University Hospitals NHS Foundation Trust Liverpool UK

12. TTPNetwork London UK

13. Department of Haematology University Hospitals Birmingham Birmingham UK

Abstract

SummaryThe objective of this guideline is to provide healthcare professionals with clear, up‐to‐date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), including complement‐mediated haemolytic uraemic syndrome (CM HUS); these are defined by thrombocytopenia, microangiopathic haemolytic anaemia (MAHA) and small vessel thrombosis. Within England, all TTP cases should be managed within designated regional centres as per NHSE commissioning for highly specialised services.

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19026

Reference160 articles.

1. Redefining outcomes in immune TTP: an international working group consensus report

2. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

3. Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura

4. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis

5. von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In a nutshell: TTP and pregnancy;British Journal of Haematology;2024-08-28

2. Refractory Thrombotic Thrombocytopenic Purpura in a Patient With Triple X Syndrome;Cureus;2024-08-23

3. Immune‐mediated thrombotic thrombocytopenic purpura with ischaemic cerebral infarction preceding onset of thrombocytopenia and microangiopathic haemolytic anaemia: A case report;British Journal of Haematology;2024-08-19

4. Diagnostic Challenges in a Case of Immune-Mediated Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency;Cureus;2024-08-18

5. Haematological problems in intensive care: recent advances and developments;Anaesthesia & Intensive Care Medicine;2024-08